Treatment of recalcitrant generalized morphea with infliximab.
Diab
Mohammad
M
Division of Dermatology, The Ohio State University Medical Center, 4731 Cramblett Hall, 456 W Tenth Ave, Columbus, OH 43210, USA. Mohammad.Diab@osumc.edu
Coloe
Jacquelyn R
JR
Magro
Cynthia
C
Bechtel
Mark A
MA
D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001706:Biopsy; D003879:Dermatologic Agents / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000069285:Infliximab; D012594:Scleroderma, Localized / Q000188:drug therapy* / Q000473:pathology; D012867:Skin / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab